Tafinlar

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2013-2017
012320132017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Approved combination therapies A combination of the two HER2 (also known as ERBB2)-targeted drugs pertuzumab (Perjeta; Roche) and… (More)
  • table 1
  • figure 1
Is this relevant?
Review
2016
Review
2016
The RAS-RAF-MEK1/2-ERK1/2 pathway is a key signal transduction pathway in the cells. Critically, it remains constitutively active… (More)
  • figure 1
  • table 2
  • table 3
  • table 3
  • figure 2
Is this relevant?
2015
2015
Despite the continuously increasing incidence of melanoma, over decades the therapy has barely changed. However, since 2011 the… (More)
Is this relevant?
Review
2015
Review
2015
Author's disclosures of potential conflicts of interest are found at the end of this article. M alignant melanoma accounts for… (More)
  • table 1
  • table 2
Is this relevant?
2015
2015
BACKGROUND In Russia, the incidence of melanoma is increasing steadily. The approved standard of specialized medical care for… (More)
Is this relevant?
2014
2014
Since patients diagnosed with BRAF V600E and V600K mutated advanced melanoma show response to treatment with MAP kinase… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • table 4
Is this relevant?
Review
2014
Review
2014
Author's disclosures of potential conflicts of interest are found at the end of this article. M elanoma, the most dangerous form… (More)
  • table 1
  • table 2
Is this relevant?
2013
2013
  • 2013
Menkinist and Tafinlar For Melanoma Two drugs made by GlaxoSmithKline—dabrafenib (Tafinlar) and trametinib (Mekinist)—have been… (More)
Is this relevant?
2013
2013
On July 9, GlaxoSmithKline of London filed an application with the US Food and Drug Administration (FDA) seeking approval of BRAF… (More)
  • table 1
Is this relevant?
2013
2013
  • The Medical letter on drugs and therapeutics
  • 2013
 
Is this relevant?